Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: A case series

International Journal of Rheumatic Diseases

Volumn 17, Issue 8, 2014, Pages 923-928

  Yilmaz, Neslihan ^a,b   Can, Meryem ^a   Kocakaya, Derya ^a   Karakurt, Sait ^a   Yavuz, Sule ^a,b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Interstitial lung disease; Mycophenolate mofetil; Scleroderma

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; ANALOGS AND DERIVATIVES; COMPLICATION; LUNG DIFFUSION CAPACITY; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; SCLERODERMA, SYSTEMIC; VITAL CAPACITY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PULMONARY DIFFUSING CAPACITY; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; VITAL CAPACITY;

EID: 84921950624     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12399     Document Type: Article

References (30)

1. Harris ED, Budd RC, Firestein GS et al. (2005) Kelley's Textbook of Rheumatology. Vol. II, pp 1279-303. Elsevier, Philadelphia.
2. Silver RM, Clements PJ (2003) Interstitial lung disease in systemic sclerosis: optimizing evaluation and management. Scleroderma Care Res 1, 1-20.
3. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisolone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20, 838-44.
4. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37, 729-35.
5. Steen VD, Lanz JK, Conte C, Ownes GR, Medsger TA (1994) Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 37, 1290-6.
6. Giacomelli R, Valentini G, Salsano F et al. (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29, 731-6.
7. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoviannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29, 298-304.
8. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18, 455-61.
9. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulsed intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29, 2371-8.
10. Tashkin DP, Elashoff R, Clements PJ et al., for the Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354, 2655-66.
11. Tashkin DP, Elashoff R, Clements PJ et al. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176, 1026-34.
12. Mittoo S, Wigley FM, Wise RA, Woods A, Xiao H, Hummers LK (2011) Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J 5, 1-6.
13. Villarroel MC, Hidalgo M, Jimeno A (2009) Mycophenolate mofetil: an update. Drugs Today 45, 521-32.
14. Allison AC, Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80 (Suppl. 2), 181-90.
15. Dooley MA, Jayne D, Ginzler EM et al. (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365, 1886-95.
16. Majithia V, Harisdangkul V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44 (3), 386-9.
17. Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133 (2), 455-60.
18. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 29 (10), 1167-8.
19. Liossis SNC, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45 (8), 1005-8.
20. Zamora AC, Wolters PJ, Collard HR et al. (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respirat Med 102 (1), 150-5.
21. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18, 1520-8.
22. Bellia M, Cannizzaro F, Scichilone N et al. (2009) HRCT and scleroderma: semi quantitative evaluation of lung damage and functional abnormalities. Radiol Med 114, 190-203.
23. Diot E, Boissinot E, Asquier E et al. (1998) Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 114, 1623-9.
24. Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10, 1-9.
25. Liossis SNC, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45, 1005-8.
26. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE (2006) Letters to the Editor: Mycophenolate mofetil for interstitial lung disease in Scleroderma. Rheumatology 45, 1572-82.
27. Tzouvelekis A, Galanopoulos N, Bouros E et al. (2012) Effect and safety of Mycophenolate mofetil or sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: a meta-analysis. Pulm Med 2012, 1-7.
28. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laqu′e R, Vilardell-Tarres M (2011) Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 30 (11), 1393-8.
29. Fischer A, Brown KK, Du Bois RM et al. (2013) Mycophenolate mofetil improves lung function in connective tissue disease associated interstitial lung disease. J Rheumatol 40 (5), 640-6.
30. Goldin JG, Lynch DA, Strollo DC et al. (2008) High resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134, 358-67.